Benjamin F. Edwards & Company, Inc. Hepion Pharmaceuticals, Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 27, 2023	SELL	$0.31 - $1.06 $310 - $1,060	-1,000 Reduced 99.9%	1 $0
Q2 2022 Aug 12, 2022	SELL	$0.57 - $1.22 $1,994 - $4,270	-3,500 Reduced 77.76%	1,001 $1,000
Q4 2021 Feb 07, 2022	SELL	$1.14 - $1.58 $2,280 - $3,160	-2,000 Reduced 30.76%	4,501 $5,000
Q2 2021 Aug 11, 2021	BUY	$1.56 - $2.26 $5,460 - $7,909	3,500 Added 116.63%	6,501 $13,000
Q1 2021 May 14, 2021	BUY	$1.77 - $2.98 $5,310 - $8,940	3,000 Added 300000.0%	3,001 $6,000
Q3 2019 Nov 05, 2019	BUY	$2.09 - $4.12 $2 - $4	1 New	1 $0

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $51.8M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.